Therapeutic misunderstandings in modern research
© 2023 The Authors. Bioethics published by John Wiley & Sons Ltd..
Clinical trials play a crucial role in generating evidence about healthcare interventions and improving outcomes for current and future patients. For individual trial participants, however, there are inevitably trade-offs involved in clinical trial participation, given that trials have traditionally been designed to benefit future patient populations rather than to offer personalised care. Failure to understand the distinction between research and clinical care and the likelihood of benefit from participation in clinical trials has been termed the 'therapeutic misconception'. The evolution of the clinical trials landscape, including greater integration of clinical trials into healthcare and development of novel trial methodologies, may reinforce the significance of the therapeutic misconception and other forms of misunderstanding while at the same time (paradoxically) challenging its salience. Using cancer clinical trials as an exemplar, we describe how methodological changes in early- and late-phase clinical trial designs, as well as changes in the design and delivery of healthcare, impact upon the therapeutic misconception. We suggest that this provides an impetus to re-examine the ethics of clinical research, particularly in relation to trial access, participant selection, communication and consent, and role delineation.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:38 |
|---|---|
| Enthalten in: |
Bioethics - 38(2024), 2 vom: 21. Feb., Seite 138-152 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Heynemann, Sarah [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Adaptive clinical trial |
|---|
| Anmerkungen: |
Date Completed 15.01.2024 Date Revised 22.03.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1111/bioe.13241 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM366063456 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM366063456 | ||
| 003 | DE-627 | ||
| 005 | 20240323000433.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231227s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/bioe.13241 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1341.xml |
| 035 | |a (DE-627)NLM366063456 | ||
| 035 | |a (NLM)38115678 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Heynemann, Sarah |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Therapeutic misunderstandings in modern research |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 15.01.2024 | ||
| 500 | |a Date Revised 22.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023 The Authors. Bioethics published by John Wiley & Sons Ltd. | ||
| 520 | |a Clinical trials play a crucial role in generating evidence about healthcare interventions and improving outcomes for current and future patients. For individual trial participants, however, there are inevitably trade-offs involved in clinical trial participation, given that trials have traditionally been designed to benefit future patient populations rather than to offer personalised care. Failure to understand the distinction between research and clinical care and the likelihood of benefit from participation in clinical trials has been termed the 'therapeutic misconception'. The evolution of the clinical trials landscape, including greater integration of clinical trials into healthcare and development of novel trial methodologies, may reinforce the significance of the therapeutic misconception and other forms of misunderstanding while at the same time (paradoxically) challenging its salience. Using cancer clinical trials as an exemplar, we describe how methodological changes in early- and late-phase clinical trial designs, as well as changes in the design and delivery of healthcare, impact upon the therapeutic misconception. We suggest that this provides an impetus to re-examine the ethics of clinical research, particularly in relation to trial access, participant selection, communication and consent, and role delineation | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Bayes theorem | |
| 650 | 4 | |a adaptive clinical trial | |
| 650 | 4 | |a clinical trials | |
| 650 | 4 | |a informed consent | |
| 650 | 4 | |a research ethics | |
| 650 | 4 | |a therapeutic misconception | |
| 700 | 1 | |a Lipworth, Wendy |e verfasserin |4 aut | |
| 700 | 1 | |a McLachlan, Sue-Anne |e verfasserin |4 aut | |
| 700 | 1 | |a Philip, Jennifer |e verfasserin |4 aut | |
| 700 | 1 | |a John, Tom |e verfasserin |4 aut | |
| 700 | 1 | |a Kerridge, Ian |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Bioethics |d 1987 |g 38(2024), 2 vom: 21. Feb., Seite 138-152 |w (DE-627)NLM086770004 |x 1467-8519 |7 nnns |
| 773 | 1 | 8 | |g volume:38 |g year:2024 |g number:2 |g day:21 |g month:02 |g pages:138-152 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1111/bioe.13241 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 38 |j 2024 |e 2 |b 21 |c 02 |h 138-152 | ||